Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review.

Journal: Pancreas
PMID:

Abstract

Despite considerable research efforts, pancreatic cancer is associated with a dire prognosis and a 5-year survival rate of only 10%. Early symptoms of the disease are mostly nonspecific. The premise of improved survival through early detection is that more individuals will benefit from potentially curative treatment. Artificial intelligence (AI) methodology has emerged as a successful tool for risk stratification and identification in general health care. In response to the maturity of AI, Kenner Family Research Fund conducted the 2020 AI and Early Detection of Pancreatic Cancer Virtual Summit (www.pdac-virtualsummit.org) in conjunction with the American Pancreatic Association, with a focus on the potential of AI to advance early detection efforts in this disease. This comprehensive presummit article was prepared based on information provided by each of the interdisciplinary participants on one of the 5 following topics: Progress, Problems, and Prospects for Early Detection; AI and Machine Learning; AI and Pancreatic Cancer-Current Efforts; Collaborative Opportunities; and Moving Forward-Reflections from Government, Industry, and Advocacy. The outcome from the robust Summit conversations, to be presented in a future white paper, indicate that significant progress must be the result of strategic collaboration among investigators and institutions from multidisciplinary backgrounds, supported by committed funders.

Authors

  • Barbara Kenner
    From the Kenner Family Research Fund, New York, NY.
  • Suresh T Chari
    Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
  • David Kelsen
    Edward S. Gordon Chair in Medical Oncology.
  • David S Klimstra
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Stephen J Pandol
    Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Michael Rosenthal
    Dana-Farber Cancer Institute, Boston, MA, USA.
  • Anil K Rustgi
    Division of Digestive and Liver Diseases, Department of Medicine, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, NY.
  • James A Taylor
    Google Health, Seattle, WA.
  • Adam Yala
    Department of Electrical Engineering and Computer Science, CSAIL, MIT, Cambridge, USA.
  • Noura Abul-Husn
    Division of Genomic Medicine, Department of Medicine, Icahn School of Medicine, Mount Sinai, New York, NY.
  • Dana K Andersen
    Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD.
  • David Bernstein
    Stand Up To Cancer, New York, NY.
  • Søren Brunak
    NNF Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.
  • Marcia Irene Canto
    Division of Gastroenterology, Johns Hopkins University School of Medicine, Baltimore, MD.
  • Yonina C Eldar
    Department of Computer Science and Applied Mathematics, Weizmann Institute of Science, Rehovot 7610001, Israel.
  • Elliot K Fishman
    The Russell H. Morgan Department of Radiology and Radiologic Science, Johns Hopkins School of Medicine, Baltimore, Maryland. Electronic address: efishman@jhmi.edu.
  • Julie Fleshman
    Pancreatic Cancer Action Network, Manhattan Beach.
  • Vay Liang W Go
    UCLA Center for Excellence in Pancreatic Diseases, University of California, Los Angeles, Los Angeles, CA.
  • Jane M Holt
    National Pancreas Foundation, Bethesda, MD.
  • Bruce Field
    From the Kenner Family Research Fund, New York, NY.
  • Ann Goldberg
    From the Kenner Family Research Fund, New York, NY.
  • William Hoos
    1440 Foundation, Chapel Hill, NC.
  • Christine Iacobuzio-Donahue
    David M. Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Debiao Li
  • Graham Lidgard
    Exact Sciences, Madison, WI.
  • Anirban Maitra
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Lynn M Matrisian
    Pancreatic Cancer Action Network, Manhattan Beach.
  • Sung Poblete
    Stand Up To Cancer, Los Angeles, CA.
  • Laura Rothschild
    From the Kenner Family Research Fund, New York, NY.
  • Chris Sander
    Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, 10065 NY; and arne@bioinfo.se debbie@hms.harvard.edu cccsander@gmail.com.
  • Lawrence H Schwartz
    Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
  • Uri Shalit
    Faculty of Industrial Engineering and Management, Technion - Israel Institute of Technology, Technion City, Haifa 3200003, Israel.
  • Sudhir Srivastava
    Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC 20037, USA, Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD 21201, USA, Center for Bioinformatics and Information Technology, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20892-9760, USA, NASA Jet Propulsion Laboratory, Pasadena, CA, USA, Division of Cancer Prevention, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20892-9760, USA, Wellcome Trust Sanger Institute, Cambridge, UK and McCormick Genomic and Proteomic Center, George Washington University, Washington, DC 20037, USA.
  • Brian Wolpin
    Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, Boston, MA.